GlobeNewsWire
22 Jul 2026, 10:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri trial failed to meet its primary endpoint of a statistically significant reduction in Stage III-IV cancers. — Failure of a primary clinical endpoint for a core product significantly impairs the company's commercial outlook and regulatory prospects.
-0.80A securities fraud class action lawsuit has been filed against GRAIL and its executives alleging they misled investors regarding the NHS-Galleri trial. — Legal proceedings for securities fraud create significant financial liability and reputational risk for the company.
-0.50GRAIL's stock price dropped approximately 50% following the disclosure of the trial's failure on February 19, 2026. — While the drop has already occurred, the magnitude confirms the market's negative valuation of the trial failure.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities fraud class action lawsuit following a 50% stock price drop and failure to meet a primary clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
